BHC
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | -5 | 75.61M | $382.82M | +3 | −8 |
| Q1 2026 | 85 | -6 | 79.75M | $438.97M | +2 | −9 |
| Q4 2025 | 92 | +1 | 89.74M | $627.51M | +2 | n/a |
| Q3 2025 | 19 | +1 | 25.30M | $166.30M | +2 | −2 |
| Q2 2025 | 16 | -1 | 54.52M | $364.89M | n/a | −1 |
| Q1 2025 | 15 | +1 | 47.24M | $307.27M | +2 | −1 |
| Q4 2024 | 14 | +1 | 50.10M | $405.72M | +1 | n/a |
| Q3 2024 | 13 | +1 | 47.82M | $391.50M | +2 | −1 |
| Q2 2024 | 12 | n/a | 55.66M | $388.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 34.72M | n/a | $242.01M | 2.2% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 7.08M | n/a | $49.33M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Arrowstreet Capital ✦ | 4.24M | n/a | $29.55M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 3.77M | n/a | $26.28M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Glenview Capital ✦ | 1.31M | n/a | $9.11M | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Oaktree Capital Management ✦ | 1.27M | n/a | $8.85M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | GAMCO Investors ✦ | 1.18M | n/a | $8.19M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 898.69K | n/a | $6.26M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 527.81K | n/a | $4.52M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 413.14K | n/a | $2.88M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Bridgewater Associates ✦ | 247.78K | n/a | $1.73M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Elliott Investment Management ✦ | 11.50K | n/a | $80,157 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 232.19M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 36.83K sh · $258,894
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology